MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Kura Oncology Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

6.4 0.79

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

6.11

Max

6.43

Pagrindiniai rodikliai

By Trading Economics

Pajamos

35M

-19M

Pardavimai

54M

54M

Pelnas, tenkantis vienai akcijai

-0.22

Pelno marža

-35.664

Darbuotojai

192

EBITDA

43M

-17M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+284.14% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-01

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-114M

499M

Ankstesnė atidarymo kaina

5.61

Ankstesnė uždarymo kaina

6.4

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

Kura Oncology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-24 23:54; UTC

Karštos akcijos

Stocks to Watch: Alphabet, Intel, AppFolio

2025-04-24 23:51; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

2025-04-24 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-04-24 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

2025-04-24 23:37; UTC

Svarbiausios naujienos

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

2025-04-24 23:36; UTC

Svarbiausios naujienos

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

2025-04-24 23:13; UTC

Svarbiausios naujienos
Uždarbis

Google's Earnings Power Holds Up in Global Turbulence -- Update

2025-04-24 23:09; UTC

Svarbiausios naujienos

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

2025-04-24 23:02; UTC

Įsigijimai, susijungimai, perėmimai

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

2025-04-24 23:02; UTC

Įsigijimai, susijungimai, perėmimai

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

2025-04-24 22:51; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

2025-04-24 22:48; UTC

Svarbiausios naujienos

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

2025-04-24 22:47; UTC

Rinkos pokalbiai

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

2025-04-24 22:38; UTC

Rinkos pokalbiai
Uždarbis

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

2025-04-24 22:24; UTC

Uždarbis

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

2025-04-24 22:24; UTC

Uždarbis

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

2025-04-24 22:24; UTC

Rinkos pokalbiai
Uždarbis

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

2025-04-24 22:23; UTC

Uždarbis

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

2025-04-24 22:11; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-04-24 22:11; UTC

Rinkos pokalbiai
Uždarbis

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

2025-04-24 22:09; UTC

Svarbiausios naujienos
Uždarbis

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

2025-04-24 22:00; UTC

Rinkos pokalbiai
Uždarbis

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

2025-04-24 21:39; UTC

Svarbiausios naujienos

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

2025-04-24 21:24; UTC

Svarbiausios naujienos
Uždarbis

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

2025-04-24 21:24; UTC

Svarbiausios naujienos
Uždarbis

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

2025-04-24 21:23; UTC

Svarbiausios naujienos
Uždarbis

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

2025-04-24 21:04; UTC

Uždarbis

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

2025-04-24 21:03; UTC

Uždarbis

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

2025-04-24 21:03; UTC

Uždarbis

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

2025-04-24 21:02; UTC

Uždarbis

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Akcijų palyginimas

Kainos pokytis

Kura Oncology Inc Prognozė

Kainos tikslas

By TipRanks

284.14% į viršų

12 mėnesių prognozė

Vidutinis 24.7 USD  284.14%

Aukščiausias 40 USD

Žemiausias 10 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Kura Oncology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

10

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

5.77 / 6.6Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.